Sherrie McCain Banned from Importing Drugs After Conviction
Published Date: 2/19/2026
Notice
Summary
Sherrie R. McCain is officially banned for 5 years from importing any drugs into the U.S. because she was convicted of bringing in a misbranded drug. She didn’t respond to the FDA’s notice or ask for a hearing, so the ban started on February 19, 2026. She can apply to end the ban anytime, but until then, no drug imports from her!
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
5-year drug-import ban for named individual
Sherrie R. McCain is banned for 5 years from importing or offering for import any drug into the United States, effective February 19, 2026. The debarment follows her October 24, 2024 felony conviction for introduction into interstate commerce of a misbranded drug, and she may apply at any time for termination of debarment under section 306(d)(1) (applications accepted via https://www.regulations.gov or by mail to Docket No. FDA-2025-N-0309).
Assisting or importing with her is prohibited
As of February 19, 2026, importing or offering for import any drug by, with the assistance of, or at the direction of Sherrie R. McCain is a prohibited act under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(cc)). Anyone who imports drugs in concert with or at the direction of Ms. McCain would be engaging in a prohibited act under the cited statute.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16714, Agency Information Collection Activities; Proposed Collection; Comment Request; Third Party Disclosure and Recordkeeping Requirements for Reportable Food
The Food and Drug Administration (FDA or the Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of FDA's third-party disclosure and recordkeeping requirements for reportable food.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16715, Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Previous / Next Documents
Previous: 2026-03250, Revocation of Authorization of Emergency Use of ExThera Medical Corporation Seraph 100 Microbind Affinity Blood Filter (Seraph 100); Availability
The FDA has officially ended the emergency use approval for ExThera Medical’s Seraph 100 blood filter as of November 24, 2025. This means hospitals and patients can no longer use this device under emergency rules. The change was requested by the company, so no surprise bills or sudden costs are expected.
Next: 2026-03253, Justin Insprucker: Final Debarment Order
Justin Insprucker is officially banned for 5 years from importing any drugs into the U.S. because he was convicted of a serious crime involving fake drugs. He didn’t respond to the FDA’s notice, so the ban started on February 19, 2026. He can apply to end the ban anytime, but must follow special rules to keep his info private.